Seminars in Nuclear Medicine
Volume 32, Issue 1 , Pages 13-34 , January 2002

Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders

  • Andrew Newberg
    • ,
  • Abass Alavi

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Abass Alavi, MD, Division of Nuclear Medicine, Hospital of the University of Pennsylvania, 110 Donner Bldg, 3400 Spruce St, Philadelphia, PA 19104.
    • ,
  • Martin Reivich

References 

  1. Reivich M, Kuhl DE, Wolf A, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127–137
  2. Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology . Assessment: Positron emission tomography. Neurology. 1991;41:163–167
  3. Shtern F. Positron emission tomography as a diagnostic tool: A reassessment based on literature review. Invest Radiol. 1992;27:165–168
  4. Budinger TF. Future developments in positron-emission tomography for incorporation into the clinical sphere. Invest Radiol. 1993;28(suppl 3):S142–S143
  5. Kuhl DE, Edwards RQ. Image separation of radioisotope scanning. Radiology. 1963;80:653–662
  6. Kuhl DE, Edwards RQ, Ricci AR, et al. The MARK IV system for radionuclide computed tomography of the brain. Radiology. 1976;121:405–413
  7. Alavi A, Hirsch LJ. Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography. Evolution over the past 2 decades. Semin Nucl Med. 1991;21:58–81
  8. Karp JS, Freifelder R, Geagan MJ, et al. Three-dimensional imaging characteristics of the HEAD PENN-PET scanner. J Nucl Med. 1997;38:636–643
  9. Ido T, Wan CN, Casella V, et al. Labeled 2-deoxyglucose analogs, 18F-labeled 2-deoxyglucose-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-manose and 14C-2-deoxy-2-fluoro-D-glucose. J Label Comp Radiopharm. 1978;14:175–183
  10. Ter-Pogossian MM, Phelps ME, Hoffman EJ, et al. A positron emission transaxial tomography for nuclear medicine imaging (PET). Radiology. 1975;114:89–98
  11. Phelps ME, Hoffman EJ, Mullani NA, et al. Design considerations for a positron emission transaxial tomo-graph (PET-III). IEEE Trans Nucl Sci NS. 1976;23:516–522
  12. Mielke R, Kessler J, Szelies B, et al. Normal and pathological aging—findings of positron-emission-tomography. J Neural Transm. 1998;105:821–837
  13. Moeller JR, Ishikawa T, Dhawan V, et al. The metabolic topography of normal aging. J Cerebr Blood Flow Metab. 1996;16:385–398
  14. Chawluk JB, Alavi A, Dann R, et al. Positron emission tomography in aging and dementia: Effect of cerebral atrophy. J Nucl Med. 1987;28:431–437
  15. Kuhl DE, Metter EJ, Riege WH, et al. Effects of human aging on patterns of local cerebral glucose utilization determined by the (18F) fluorodeoxyglucose method. J Cereb Blood Flow Metab. 1982;2:163–171
  16. deLeon M, George A, Tomanelli J, et al. Positron emission tomography studies of normal aging, a replication of PET III and 18-FDG using PET IV and II-CDG. Neurobiol Aging. 1987;8:319–323
  17. Weiss D, Souder E, Alavi A, et al. Effects of normal aging on whole brain and regional glucose metabolism as assessed by F-18 positron emission tomography. J Nucl Med. 1990;31:771
  18. Eberling JL, Nordhal TE, Kusubov N, et al. Reduced temporal lobe glucose metabolism in aging. J Neuroimaging. 1995;5:178–182
  19. Murphy DGM, DeCarli C, McIntosh AR, et al. Sex differences in human brain morphometry and metabolism: An in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging. Arch Gen Psychiatry. 1996;53:585–594
  20. Cabeza R, Anderson ND, Houle S, et al. Age-related differences in neural activity during item and temporal-order memory retrieval: A positron emission tomography study. J Cog Neurosci. 2000;12:197–206
  21. Reuter-Lorenz PA, Jonides J, Smith EE, et al. Age differences in the frontal lateralization of verbal and spatial working memory revealed by PET. J Cog Neurosci. 2000;12:174–187
  22. Cabeza R, Grady CL, Nyberg L, et al. Age-related differences in neural activity during memory encoding and retrieval: A positron emission tomography study. J Cog Neurosci. 1997;17:391–400
  23. Della-Maggiore V, Sekuler A, Grady CL, et al. Corticolimbic interactions associated with performance on a short-term memory task are modified by age [accessed on-line]. J Neurosci. 2000;20:8410–8416
  24. Calcutti C, Serrati C, Baron JC. Effects of age on brain activation during auditory-cued thumb-to-index opposition: A positron emission tomography study [accessed on-line]. Stroke. 2001;32:139–146
  25. Levine BK, Beason-Held LL, Purpura KP. Age-related differences in visual perception: A PET study. Neurobiol Aging. 2000;21:577–584
  26. McIntosh AR, Sekuler AB, Penpeci C, et al. Recruitment of unique neural systems to support visual memory in normal aging. Current Biol. 1999;9:1275–1278
  27. Grady CL, McIntosh AR, Bookstein F. Age-related changes in regional cerebral blood flow during working memory for faces. Neuroimage. 1998;8:409–425
  28. Madden DJ, Turkington TG, Provenzale JM, et al. Adult age differences in the functional neuroanatomy of verbal recognition memory. Hum Brain Mapp. 1999;7:115–135
  29. Hazlett EA, Buchsbaum MS, Mohs RC, et al. Age-related shift in brain region activity during successful memory performance. Neurobiol Aging. 1998;19:437–445
  30. Yoshii F, Barker WW, Chang JY, et al. Sensitivity of cerebral glucose metabolism to age, gender, brain volume, brain atrophy, and cerebrovascular risk factors. J Cerebr Blood Flow Metab. 1988;8:654–661
  31. Clark C, Hayden M, Hollenberg S, et al. Controlling for cerebral atrophy in positron emission tomography data. J Cerebr Blood Flow Metab. 1987;7:510–512
  32. Alavi A, Newberg A, Souder E, et al. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: Atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med. 1993;34:1681–1687
  33. Schlageter NL, Horwitz B, Creasey H, et al. Relation of measured brain glucose utilization and cerebral atrophy in man. J Neurol Neurosurg Psychiatry. 1987;50:779–785
  34. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  35. Tierney MC, Gisher RH, Lewis AJ, et al. The NINCDS-ADRDA Workgroup criteria for the clinical diagnosis of probable Alzheimer's disease. A clinical pathological study of 57 cases. Neurology. 1988;38:359–364
  36. Joachim CL, Morris JH, Selkow DJ. Clinical diagnosed Alzheimer's disease. Autopsy results in 150 cases. Ann Neurol. 1988;24:50–56
  37. Friston KJ, Frackowiak RS. Cerebral function in aging and Alzheimer's disease. The role of PET. Electroencephalogr Clin Neurophysic Suppl. 1991;42:355–365
  38. Frackowiak RS. PET: Studies in dementia. Psychiatry Res. 1989;29:353–355
  39. Haxby JC, Grady CL, Koss E, et al. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. Neurology. 1988;38:1853–1863
  40. Sheridan PH, Sato S, Foster N, et al. Relatons of EEG alpha background to parietal lobe function in Alzheimer's disease as measured by positron emission tomography and psychometry. Neurology. 1988;38:747–750
  41. Alavi A, Reivich M, Ferris S, et al. Regional cerebral glucose metabolism in aging and senile dementia as determined by 18F-deoxyglucose and positron emission tomography. In: Hoyer S editors. The aging brain—physiological and pathophysiological aspects. Berlin: Springer-Verlag; 1982;p. 87–195
  42. Heiss WD, Kessler J, Szelies B, et al. Positron emission tomography in the differential diagnosis of organic dementias. J Neural Transm Suppl. 1991;33:13–19
  43. Jamieson DG, Chawluck JB, Alavi A, et al. The effect of disease severity on local cerebral glucose metabolism in Alzheimer's disease. J Cerebr Blood Flow Metab. 1987;7:S410
  44. Kumar A, Schapiro MB, Grady C, et al. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology. 1991;4:35–46
  45. Faulstich ME, Sullivan DC. Positron emission tomography in neuropsychiatry. Invest Radiol. 1991;26:184–194
  46. Bonte FJ, Hom J, Tinter R, et al. Single photon tomography in Alzheimer's disease and the dementias. Semin Nucl Med. 1990;20:342–352
  47. abstr Friedland RP, Grady CL, Shapiro MB, et al. Family history of dementia and regional cerebral glucose utilization (rCMRgle) in dementia of the Alzheimer type (AD). Neurol. 1989;39(suppl 1):168
  48. Rapoport SI, Horowitz B, Grady CL, et al. Abnormal brain glucose metabolism in Alzheimer's disease as measured by positron emission tomography. Adv Exp Med Biol. 1991;291:231–248
  49. Ichimiya A, Herholz K, Mielke R, et al. Difference of regional cerebral metabolic pattern between presentile and senile dementia of the Alzheimer type: A factor analytic study. J Neurol Sci. 1994;123:11–17
  50. (abstr) Kuhl DE, Small GW, Riege WH, et al. Cerebral metabolic patterns before the diagnosis of probable Alzheimer's disease. J Cereb Flood Flow Metab. 1987;7:406
  51. McGeer PL, Kamo H, Harrop R, et al. Comparison of PET, MRI and CT with pathology in a proven case of Alzheimer's disease. Neurology. 1986;36:1569–1574
  52. Cutler NR, Haxby JC, Duara R, et al. Brain metabolism as measured with positron emission tomography. Serial assessment in a patient with familial Alzheimer's disease. Neurology. 1985;35:1556–1561
  53. Frackowiak R, Pozilli C, Legg N, et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron emission tomography. Brain. 1981;104:753–788
  54. Foster NL, Mann U, Mohr E, et al. Focal cerebral glucose hypometabolism in definite Alzheimer's disease. Ann Neurol. 1989;26:132–133
  55. Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med. 1992;22:232–246
  56. (abstr) Newberg A, Alavi A, Souder E, et al. A comparison of FDG PET and MRI data from patients with atypical dementias and Alzheimer's disease (AD). J Nucl Med. 1992;33:965
  57. Newberg A, Alavi A, Clark C. Comparison of FDG PET and levels of Tau protein in the diagnosis of patients with dementia. J Nucl Med. 2000;41:64P
  58. Jelic V, Nordberg A. Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord. 2000;14(suppl 1):S109–S113
  59. Cohen RM, Andreason PJ, Sunderland T. The ratio of mesial to neocortical temporal lobe blood flow as a predictor of dementia. J Am Geriatr Soc. 1997;45:329–333
  60. Kennedy AM, Rossor MN, Frackowiak RS. Positron emission tomography in familial Alzheimer disease. Alzheimer Dis Assoc Disord. 1995;9:17–20
  61. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752–758
  62. Hirono N, Mori E, Yasuda M, et al. Lack of association of apolipoprotein E epsilon 4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alzheimer Dis Assoc Disord. 1998;12:362–367
  63. Corder EH, Jelic V, Basun H, et al. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol. 1997;54:273–277
  64. Newberg A, Alavi A, Clark C. The metabolic imaging severity rating scale (MISRS) in Alzheimer's disease: Comparison with quantitative data. Eur J Nucl Med. 1998;25:1068
  65. Jagust WJ, Friedland RP, Budinger TF, et al. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology. 1988;38:909–912
  66. Kushner M, Tobin M, Alavi A, et al. Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET. J Nucl Med. 1987;28:1667–1670
  67. Chase TN, Foster NL, Fedio P, et al. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann Neurol. 1984;15:S170–S174
  68. Haxby JC, Duara R, Grady CL, et al. Relationship between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cerebr Blood Flow Metab. 1985;5:193–200
  69. McGeer EG, Peppard RP, McGeer PL, et al. 18-Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases. Can J Neurol Sci. 1990;17:1–11
  70. Grady CL, Haxby JV, Schlageter NL, et al. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology. 1986;36:1390–1392
  71. Alavi A, Jolles PR, Jamieson DG, et al. Anatomic and functional changes of the brain in normal aging and dementia as demonstrated by MRI, CT, and PET. Nucl Med Ann. 1989;49–79
  72. Koss E, Friedland RP, Ober BA. Differences in lateral hemispheric asymmetries of glucose utilization between early-and late-onset Alzheimer type dementia. Am J Psych. 1985;142:638–640
  73. Teipel SJ, Hampel H, Pietrini P, et al. Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. Arch Neurol. 1999;56:467–473
  74. Fazekas F, Alavi A, Chawluk JB, et al. Comparison of CT, MR and PET in Alzheimer's dementia and normal aging. J Nucl Med. 1989;30:1607–1615
  75. Haxby JC, Grady CL, Duara R, et al. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer'stype dementia. Arch Neurol. 1986;43:882–885
  76. Tanna NK, Kohn MI, Horwich DN, et al. Analysis of brain and cerebrospinal fluid volumes with MR imaging. Impact on PET data, correction for atrophy. Radiology. 1991;178:123–130
  77. Chawluk JB, Dann R, Alavi A, et al. The effect of focal cerebral atrophy in positron emission tomographic studies of aging and dementia. Nucl Med Biol. 1990;17:797–804
  78. Labbe C, Froment JC, Kennedy A, et al. Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging. Alzheimer Dis Assoc Disord. 1996;10:141–170
  79. (abstr) Alavi A, Newberg A, Souder E, et al. Is absolute whole brain glucose metabolism a sensitive marker for Alzheimer's disease?. J Nucl Med. 1992;33:940
  80. Newberg A, Alavi A, Clark C, et al. Metabolic imaging severity rating scale (MISRS) for the assessment of cerebral dysfunction in Alzheimer's disease. J Nucl Med. 1997;38:129P
  81. Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol. 1982;11:592–598
  82. Gordon B, Selnes Q. Progressive aphasia “without dementia:” Evidence of more widespread involvement. Neurology. 1984;34:102
  83. Luzzatti C, Poeck K. An early description of slowly progressive aphasia. Arch Neurol. 1991;48:228–229
  84. Shuttleworth EC, Huber SJ. The naming disorder of dementia of Alzheimer type. Brain Lung. 1988;34:222–234
  85. Sapin LR, Anderson FH, Pulaski PD. Progressive aphasia without dementia: Further documentation. Ann Neurol. 1989;25:411–413
  86. Chawluk JB, Mesulam MM, Hurtig H, et al. Slowly progressive aphasia without generalized dementia: Studies with positron emission tomography. Ann Neurol. 1986;19:68–74
  87. Tyrrell PJ, Warrington EK, Frackowiak RSJ, et al. Heterogeneity in progressive aphasia due to focal cortical atrophy. Brain. 1990;113:1321–1336
  88. Hachisuka K, Uchida M, Nozaki Y, et al. Primary progressive aphasia presenting as conduction aphasia. J Neurol Sci. 1999;167:137–141
  89. Kempler D, Metter EJ, Riege WH, et al. Slowly progressive aphasia: Three cases with language, memory, CT and PET data. J Neurol Neurosurg Psychiatry. 1990;53:987–993
  90. (abstr) Newberg A, Alavi A, Souder E, et al. Quantitative PET and MRI analysis in patients with primary progressive aphasia (PPA). J Nucl Med. 1992;33:857
  91. (abstr) Kamo H, McGeer PL, Harrop R, et al. Positron emission tomography and histopathology in Pick's disease. Neurology. 1988;38:228
  92. Kamo H, McGeer R, Harrop R, et al. Positron emission tomography and histopathology in Pick's disease. Neurology. 1987;37:439
  93. Salmon E, Maquet P, Sadzot B, et al. Positron emission tomography in Alzheimer's and Pick's disease. J Neurol. 1988;235:S1
  94. Lieberman AP, Trojanowski JQ, Lee VM, et al. Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease. Ann Neurol. 1998;43:259–265
  95. Rougemont D, Baron JC, Collard P, et al. Local cerebral glucose utilization in treated and untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1984;47:824–830
  96. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson's disease. Complementary (18F) fluorodeoxyglucose and (18F) fluorodopa positron emission tomographic studies. Mov Disord. 1990;5:203–213
  97. Martin WRW, Beckman JH, Calne DB, et al. Cerebral glucose metabolism in Parkinson's disease. Can J Neurol Sci. 1984;11:169–173
  98. Martin WRW, Stoessel AJ, Adam MJ, et al. Cerebral glucose metabolism in Parkinson's disease. Can J Neurol Sci. 1984;11:169–173
  99. Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the (18F) fluorodeoxyglucose method. Ann Neurol. 1984;15:419–424
  100. (suppl) Kuhl DE, Metter EJ, Riege WH, et al. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease. Ann Neurol. 1984;15:S119–S125
  101. Przedborski S, Goldman S, Giladi N, et al. Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome. Adv Neurol. 1993;60:501–505
  102. Dethy S, Van Blercom N, Damhaut P, et al. Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism. Mov Disord. 1998;13:275–280
  103. Blesa R, Blin J, et al. Levodopa-reduced glucose metabolism in striatopallidothalamocortico circuit in Parkinson's disease. Neurology. 1991;41:359
  104. Jenkins IH, Fernandez W, Playford ED, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol. 1992;32:749–757
  105. Mazziotta JC. Movement disorders. In: Maziotta JC, Gilman S editor. Clinical Brain Imaging: Principles and Applications. Philadelphia: Davis; 1992;p. 244–293
  106. Peppard RF, Martin WR, Clark CM, et al. Cortical glucose metabolism in Parkinson's and Alzheimer's disease. J Neurosci Res. 1990;27:561–568
  107. (abstr) Kuhl DE, Metter EJ, Benson DF, et al. Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia. J Nucl Med. 1985;26:P69
  108. Mazziotta JC. Huntington's disease: Studies with structural imaging techniques and positron emission tomography. Semin Neurol. 1989;9:360–369
  109. Kuhl DE, Phelps ME, Markham CH, et al. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol. 1982;12:425–434
  110. Kuwert T, Lange HW, Langin KJ, et al. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntingdon's disease. Psychiatry Res. 1989;29:361–362
  111. Pahl JJ. Cerebral metabolic decline. A biochemical marker of genetic expression in Huntington's disease. Adv Funct Neuroimaging. 1989;2:3–8
  112. Mazziotta JC, Phelps ME, Pahl JJ, et al. Reduced cerebral glucose metabolism in asymptomatic patients at risk for Huntington's disease. N Engl J Med. 1987;316:357–362
  113. (suppl) Brooks DJ, Frackowiak RSJ. PET and movement disorders. J Neurol Neurosurg Psychiatry. 1989;52:S68–S77
  114. Hayden MR aiMartin^WRW, Stoessl AJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology. 1986;36:888–894
  115. Bachoud-Levi AC, Remy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet. 2000;356:1975–1979
  116. Kuwert T, Lange HW, Langen KJ, et al. Corticsal and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 1990;113:1405–1423
  117. Young AV, Penney JB, Starosta-Rubinstein S, et al. PET scan investigations of Huntington's disease. Cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986;29:296–303
  118. Berent S, Goerdani B, Lehtinen S, et al. Positron emission tomographic scan investigations of Huntington's disease. Cerebral metabolic correlates of cognitive function. Ann Neurol. 1988;23:541–546
  119. Kuwert T, Sures T, Herzog H, et al. On the influence of spatial resolution and of the size and form of regions of interest on the measurement of regional cerebral metabolic rates by positron emission tomography. J Neural Transm Suppl. 1992;37:53–66
  120. Hayden MR, Hewitt J, Martin WRW, et al. Studies in persons at risk for Huntington's disease. N Engl J Med. 1987;317:382–383
  121. Hayden MR, Hewitt J, et al., Stoessl AJ The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology. 1987;37:1441–1447
  122. Young AB, Penney JB, Starosta-Rubinstein S, et al. Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch Neurol. 1987;44:254–257
  123. Chase TN, Tamminga CA, Burrows H. Positron emission tomographic studies of regional cerebral glucose metabolism in idiopathic dystonia. Adv Neurol. 1988;50:237–241
  124. Gilman S, Junck L, Young AB, et al. Cerebral metabolic activity in idiopathic dystonia studied with positron emission tomography. Adv Neurol. 1988;50:231–236
  125. Stoessl AJ, Martin WRW, Clark C, et al. PET studies of cerebral glucose metabolism in idiopathic torticollis. Neurology. 1986;36:653–657
  126. Foster NL, Gilman S, Berent S, et al. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol. 1988;24:399–406
  127. Goffinet AM, De Volder AG, Gillain C, et al. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann Neurol. 1989;25:131–139
  128. D'Antona R, Baron JC, Samson Y, et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain. 1985;108:785–799
  129. Yamauchi H, Fukuyama H, Nagahama Y, et al. Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy. Ann Neurol. 1997;41:606–614
  130. Santens P, De Reuck J, Crevits L, et al. Cerebral oxygen metabolism in patients with progressive supranuclear palsy: A positron emission tomography study. Eur Neurol. 1997;37:18–22
  131. Leenders KL, Frackowiak RSJ, Lees AJ. Steel-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow, and fluorodopa uptake measured by positron emission tomography. Brain. 1988;111:615–630
  132. Kuhl DE, Engel J, Phelps ME, et al. Epileptic patterns of local cerebral metabolism and perfusion in humans detemined by emission computed tomography of 18FDG and 13NH3. Ann Neurol. 1980;8:348–360
  133. Abou-Khalil BW, Siegel GJ, Sackellares JC, et al. Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy. Ann Neurol. 1987;22:480–486
  134. Engel J, Brown WJ, Kuhl DE, et al. Pathologic findings underlying focal temporal lobe hypometabolism in partial epilepsy. Ann Neurol. 1982;12:518–528
  135. Engel J, Kuhl DE, Phelps ME, et al. Comparative localization of the epileptic foci in partial epilepsy by PCT and EEG. Ann Neurol. 1982;12:529–537
  136. Engel J, Kuhl DE, Phelps ME, et al. Local cerebral metabolism during partial seizures. Neurology. 1983;33:400–413
  137. Theodore WH, Brooks R, Sato S, et al. The role of positron emission tomography in the evaluation of seizure disorders. Ann Neurol. 1984;15(suppl):S1176–S1179
  138. Theodore WH, Newmark ME, Sato S, et al. 18F-fluorodeoxyglucose positron emission tomography in refractory complex partial seizures. Ann Neurol. 1983;13:537
  139. Henry TR, Sutherling WW, Engel J, et al. Interictal cerebral metabolism in partial epilepsies of neocortical origin. Epilepsy Res. 1991;10:174–182
  140. Engel J. PET scanning in partial epilepsy. Can J Neurol Sci. 1991;18(Suppl):588–592
  141. Duncan R. Epilepsy, cerebral blood flow, and cerebral metabolic rate. Cerebrovasc Brain Metab Rev. 1992;4:105–121
  142. Utsubo H, Chuang SH, Hwang PA, et al. Neuroimaging for investigation of seizures in children. Pediatr Neurosurg. 1992;18:105–116
  143. Breier JI, Mullani NA, Thomas AB, et al. Effects of duration of epilepsy on the uncoupling of metabolism and blood flow in complex partial seizures. Neurology. 1997;48:1047–1053
  144. Spanaki MV, Kopylev L, Liow K, et al. Relationship of seizure frequency to hippocampus volume and metabolism in temporal lobe epilepsy. Epilepsia. 2000;41:1227–1229
  145. Savic I, Altshuler L, Baxter L, et al. Pattern of interictal hypome-tabolism in PET scans with fludeoxyglucose F 18 reflects prior seizures types in patients with mesial temporal lobe seizures. Arch Neurol. 1997;54:129–136
  146. Engel J, Babb TL, Phelps ME. Contributions of positron emission tomography to understanding mechanisms of epilepsy. In: Engel J, Ojemann GA, Luders HO, et al. editor. Fundamental Mechanisms of Human Brain Function. New York: Raven Press; 1987;p. 209–218
  147. Theodore WH, Katz D, Kufta C, et al. Pathology of temporal lobe foci: Correlation with CT, MRI and PET. Neurol. 1990;40:797–803
  148. Theodore WH, Gaillard WD, Sato S, et al. Positron emission tomographic measurement of cerebral blood flow and temporal lobectomy. Ann Neurol. 1994;36:241–244
  149. Manno EM, Sperling MR, Ding X, et al. Predictors of outcome after anterior temporal lobectomy: Positron emission tomography. Neurology. 1994;44:2331–2336
  150. Radtke RA, Hanson MW, Hoffman JM, et al. Temporal lobe hypometabolism on PET: Predictor of seizure control after temporal lobectomy. Neurology. 1993;43:1088–1092
  151. Wong C-Y, Geller EB, Chen EQ, et al. Outcome of temporal lobe epilepsy surgery predicted by statistical parametric PET imaging. J Nucl Med. 1996;37:1094–1100
  152. Theodore WH, Sato S, Kufta C, et al. Temporal lobectomy for uncontrolled seizures: The role of positron tomography. Ann Neurol. 1992;32:789–794
  153. Delbeke D, Lawrence SK, Abou-Khalil BW, et al. Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography. Invest Radiol. 1996;31:261–266
  154. Benbadis SR, So NK, Antar MA, et al. The value of PET scan (and MRI and Wada test) in patients with bitemporal epileptiform abnormalities. Arch Neurol. 1995;52:1062–1068
  155. Swartz BE, Tomiyasu U, Delgado-Escueta AV, et al. Neuroimaging in temporal lobe epilepsy: Test sensitivity and relationships to pathology and postoperative outcome. Epilepsia. 1992;33:624–634
  156. 92P Newberg A, Alavi A, Sperling M, et al. Thalamic metabolic asymmetry on FDG PET scans as a determinant of seizure outcome after temporal lobectomy. J Nucl Med. 1997;38:
  157. Verity CM, Strauss EH, Moyes PD, et al. Long-term follow-up after cerebral hemispheroctomy. Neurophysiologic, radiologic, and psychological findings. Neurology. 1982;32:629
  158. Akimura T, Yeh HS, Mantil JC, et al. Cerebral metabolism of the remote area after epilepsy surgery. Neurologia Medico-Chirurgica. 1999;39:16–25
  159. Engel J, Kuhl DE, Phelps ME. Patterns of human local cerebral glucose metabolism during epileptic seizures. Science. 1982;218:64–66
  160. Theodore WH, Fishbein D, Dubinsky R. Patterns of cerebral glucose metabolism in patients with partial seizures. Neurol. 1988;38:1201–1206
  161. Markand ON, Salanova V, Worth R, et al. Comparative study of interictal PET and ictal SPECT in complex partial seizures. Acta Neurol Scand. 1997;95:129–136
  162. Salanova V, Markand O, Worth R, et al. FDG PET and MRI in temporal lobe epilepsy: Relationship to febrile seizures, hippocampal sclerosis and outcome. Acta Neurol Scand. 1998;97:146–153
  163. Knowlton RC, Laxer KD, Ende G, et al. Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy. Ann Neurol. 1997;42:829–837
  164. Bernardi S, Trimble MR, Frackowiak RSJ, et al. An interictal study of partial epilepsy using positron emission tomography and oxygen-15 inhalation method. J Neurol Neurosurg Psychiatr. 1983;46:473–477
  165. Franck G, Maquet P, Sadzot B, et al. Contribution of positron emission tomography to the investigation of epilepsies of frontal lobe origin. Adv Neurol. 1992;57:471–485
  166. Och RF, Yamamoto Y, Gloor P. Correlations between the positron emission tomography measurement of glucose metabolism and oxygen utilization in focal epilepsy. Neurology. 1984;34(Suppl 1):125
  167. Sperling M, Wilson G, Engel J, et al. Magnetic resonance imaging in intractable partial epilepsy: Correlative studies. Ann Neurol. 1986;20:57–62
  168. Rubin E, Dhawan V, Moeller JR, et al. Cerebral metabolic topography in unilateral temporal lobe epilepsy. Neurology. 1995;45:2212–2223
  169. Van Bogaert P, Massager N, Tugendhaft P, et al. Statistical parametric mapping of regional glucose metabolism in mesial temporal lobe epilepsy. Neuroimage. 2000;12:129–138
  170. Quesney LF, Gloor P. Localization of epileptic foci. In: Gortman J, Ives JR, Gloor P editor. Long-Term Monitoring in Epilepsy. EEG supplement 37. Amsterdam: Elsevier Science Publishers; 1985;
  171. Quesney LF, Olivier A, Andermann F, et al. Preoperative EEG investigation in patients with frontal lobe epilepsy: Trends, results and pathophysiological considerations. J Clin Neurophysiol. 1987;4:208–209
  172. Quesney LY. Extracranial EEG evaluations. In: Engel J editors. Surgical treatment of the epilepsies. New York: Raven Press; 1987;
  173. Rasmussen T. Surgery of frontal lobe epilepsy. In: Purpura DP, Penry JK, Walter RD editor. Advances in Neurology. vol 8:New York: Raven Press; 1975;
  174. Franck G, Maquet P, Sadzot B, et al. Contribution of positron emission tomography to the investigation of epilepsies of frontal lobe origin. Adv Neurol. 1992;57:471–484
  175. Robitaille Y, Rasmussen T, Dubeau F, et al. Histopathology of nonneoplastic lesions in frontal lobe epilepsy: Review of 180 cases with recent MRI and PET correlations. Adv Neurol. 1992;57:499–511
  176. Alavi A, Hirsch LJ. Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography. Evolution over the past 2 decades. Semin Nucl Med. 1991;21:58–81
  177. Chugani HT, Rintahaka PJ, Shewmon DA. Ictal patterns of cerebral glucose utilization in children with epilepsy. Epilepsia. 1994;35:813–822
  178. Theodore WH, Balish M, Leiderman D, et al. Effect of seizures on cerebral blood flow measured with 15O-H2O and positron emission tomography. Epilepsia. 1996;37:796–802
  179. Chugani HT, Shields WD, Shewmon DA, et al. Infantile spasms. I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment. Ann Neurol. 1990;27:406–413
  180. Chugani HT. Childhood epilepsy. Anatomical and functional neuroimaging. In: Ohtahara S, Roger J editor. New trends in pediatric epileptology. Satellite meeting of the joint convention of the 5th Inter Child Neurol Congress and 3rd Asian and Oceanic Congress of Child Neurol. Japan. 1990;p. 17–29
  181. Chugani HT. The use of positron emission tomography in the clinical assessment of epilepsy. Semin Nucl Med. 1992;22:247–253
  182. Chugani HT, Shewmon DA, Sankar R, et al. Infantile spasms. II. Lenticular nuclei and brain stem activation on positron emission tomography. Ann Neurol. 1992;31:212–219
  183. Chugani HT, Mazziotta JC, Engel J, et al. Lennox-Gastaut syndrome. Metabolic subtypes determined by 18-FDG positron emission tomography. Ann Neurol. 1987;21:4–13
  184. Theodore WH, Rose D, Patronas N, et al. Cerebral glucose metabolism in the Lennox-Gastaut syndrome. Ann Neurol. 1987;21:14–21
  185. Angelini L, Broggi G, Riva D, et al. A case of Lennox-Gastaut syndrome successfully treated by removal of a parietotemporal astrocytoma. Epilepsia. 1979;20:665–669
  186. Hoffman HJ, Hendrick EB, Dennis M, et al. Hemispherectomy for Sturge-Weber syndrome. Child's Brain. 1979;5:233
  187. Chugani HT, Mazziotta JC, Phelps ME. Sturge-Weber syndrome: A study of cerebral glucose utilization with positron emission tomography. J Pediatr. 1989;114:244–253
  188. Langfitt TW, Obrist WD, Alavi A, et al. Computerized tomography, magnetic resonance imaging, and positron emission tomography in the study of brain trauma. Preliminary observations. J Neurosurg. 1986;64:760–767
  189. (abstr) Alavi A, Fazekas T, Alves W, et al. Positron emission tomography in the evaluation of head injury. J Cerebr Blood Flow Metab. 1987;7:S646
  190. (abstr) George JK, Alavi A, Zimmerman RA, et al. Metabolic (PET) correlates of anatomic lesions (CT/MRI) produced by head trauma. J Nucl Med. 1989;30:802
  191. Alavi A. Functional and anatomic studies of head injury. J Neuropsychiatry. 1989;1:S45–S50
  192. Alavi A, Mirot A, Newberg A, et al. F-18 PET evaluation of crossed cerebellar diaschisis in head injury. J Nucl Med. 1997;38:1717
  193. Ruff RM, Crouch JA, Troster AI, et al. Selected cases of poor outcome following minor brain trauma: Comparing neuropsychological and positron emission tomography assessment. Brain Inj. 1994;8:297–308
  194. Bergsneider M, Hovda DA, Lee SM, et al. Dissociation of cerebral glucose metabolism and level of consciousness during the period of metabolic depression following human traumatic brain injury. J Neurotrauma. 2000;17:389–401
  195. Bergsneider M, Hovda DA, Shalmon E, et al. Cerebral hyperglycolysis following severe traumatic brain injury in humans: A positron emission tomography study. J Neurosurg. 1997;86:241–251
  196. Baron J, Frackowiak R, Herholz K, et al. Use of PET methods for measurement of cerebral energy metabolism and hemodynamics in cerebrovascular disease. J Cerebr Blood Flow Metab. 1989;9:723–742
  197. Baron J, Lebiun-Granolie P, Collar P, et al. Noninvasive measurement of blood flow, oxygen consumption and glucose utilization in the same brain regions in man by positron emission tomography. Concise communication. J Nucl Med. 1982;23:391–399
  198. Frackowiak R, Wise R. Positron tomography in ischemia cerebrovascular disease. Neurol Clin. 1983;1:183–201
  199. Herboiz K, Heiss W. Use of PET to evaluate acute stroke and other cerebrovascular disorders. In: Diksic M, Reba R editor. Radiopharmaceuticals and brain pathology studies with PET and SPECT. Boca Raton: CRC; 1991;p. 217–239
  200. Brooks DJ. The clinical role of PET in cerebrovascular disease. Neurosurg Rev. 1991;14:91–96
  201. Kushner M, Reivich M, Fieschi C, et al. Metabolic and clinical correlates of acute ischemic infarction. Neurology. 1987;37:1103–1110
  202. Ackerman R, Correia J, Alpert N, et al. Positron imaging in is-chemic stroke disease using compound labeled with oxygen-15. Arch Neurol. 1981;38:537–543
  203. Baron J, Bousser M, Comar D, et al. Noninvasive tomographs study of cerebral blood flow and oxygen metabolism in vivo. Eur Neurol. 1981;20:273–284
  204. (abstr) Baron J, Rougemont D, Bousser M, et al. Local CBF, oxygen extraction fraction (OEF) and CMRO2. Prognostic value in recent supratentorial infarction in humans. J Cerebr Blood Flow Metab. 1983;3:2
  205. Lenzi G, Frackowiak R, Jonres T. Cerebral oxygen metabolism and blood flow in human cerebral ischemic infarction. J Cerebr Blood Flow Metab. 1982;2:321–335
  206. Kuhl DE, Phelps M, Kowell A, et al. Effects of stroke on local cerebral metabolism and perfusion. Mapping by emission tomography of 18FDG and 12NH3. Ann Neurol. 1980;8:47–69
  207. Yao H, Sadoshima A, Kuwabara Y, et al. Cerebral blood flow and oxygen metabolism in patients with vascular dementia of the Binswanger type. Stroke. 1990;21:1694–1699
  208. Feeney D, Baron J. Diaschisis. Stroke. 1986;17:817–830
  209. Kushner M, Alavi A, Reivich M, et al. Contralateral cerebellar hypometabolism following cerebral insult. A positron emission tomographics study. Ann Neurol. 1984;15:425–434
  210. Kushner M, Fieschi C, Reivich M, et al. Focal and remote dysmetabolism in stroke. In: Hartmann A, Kuschinsky W editor. Cerebral ischemia and hemorology. Berlin: Springer-Verlag; 1987;
  211. Pantano P, Baron J, Samson Y, et al. Crossed cerebellar diaschisis. Further studies. Brain. 1986;109:634–677
  212. Herholz K, Heindel W, Rackl A, et al. Regional cerebral blood flow in leukoaraiosis and artherosclerotic carotid disease. Arch Neurol. 1990;47:392–397
  213. Powers J, Grubb R, Raichle M. Physiological response to focal cerebral ischemia in humans. Ann Neurol. 1984;16:546–552
  214. Iglesias S, Marchal G, Viader F, et al. Delayed intrahemispheric remote hypometabolism. Correlations with early recovery after stroke. Cerebrovasc Dis. 2000;10:391–402
  215. Baron J, Bousser M, Comar D, et al. Crossed cerebellar disaschisis in human supratentorial brain infarction. Trans Am Neurol Assoc. 1980;105:459–461
  216. Baron J, Bousser MG, Comar D. Crossed cerebellar diachisis. A remote functional depression secondary to supratentorial infarction in man. J Cerebr Blood Flow Metab. 1981;1:S500–S501
  217. De Reuck J, Decoo D, Lemahieu I, et al. Crossed cerebellar diaschisis after middle cerebral artery infection. Clin Neurol Neurosurg. 1997;99:11–16
  218. Broich K, Alavi A, Kushner M. Positron emission tomography in cerebrovascular disorders. Semin Nucl Med. 1992;22:224–232
  219. Heiss WD, Kessler J, Karbe H, et al. Cerebral glucose metabolism as a predictor of recovery from aphasia in ischemic stroke. Arch Neurol. 1993;50:958–964
  220. Powers W, Fox P. Positron emission tomography measurements of cerebral blood flow and metabolism. How can they be used to study functional recovery from stroke? (An American perspective). In: Ginsberg M, Dietrich W editor. Cerebrovascular diseases (16th research Princeton conference). New York: Raven Press; 1989;
  221. Heiss W, Pawlik G, Hebold I, et al. Can positron emission tomography be used to gauge the brain's capacity for functional recovery following stroke?. In: Ginsberg M, Dietrich W editor. Cerebrovascular diseases (16th research Princeton conference). New York: Raven Press; 1989;p. 345–352
  222. Karbe H, Kessler J. Long-term prognosis of poststroke aphasia studied with positron emission tomography. Arch Neurol. 1995;52:186–190
  223. Rosen HJ, Petersen SE, Linenweber MR, et al. Neural correlates of recovery from aphasia after damage to left inferior frontal cortex. Neurology. 2000;55:1883–1894
  224. Heiss WD, Grond M, Thiel A, et al. Tissue at risk of infarction rescued by early reperfusion: A positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J Cerebr Blood Flow Metab. 1998;18:1298–1307
  225. Heiss WD, Graf R, Grond M, et al. Quantitative neuroimaging for the evaluation of the effect of stroke treatment. Cerebrovasc Dis. 1998;8(Suppl 2):23–29
  226. Wilson CB. Metabolic imaging of human brain tumors. Semin Neurol. 1989;9:388–393
  227. DiChiro G. Positron emission tomography using (18F) fluorode-oxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol. 1986;22:360–371
  228. Hustinx R, Alavi A. SPECT and PET imaging of brain tumors. Neuroimaging Clin N Am. 1999;9:751–766
  229. (abstr) Alavi J, Alavi A, Dann R, et al. Metabolic brain imaging correlated with clinical features and brain tumors. J Nucl Med. 1985;18:P64
  230. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer. 1988;62:1074–1078
  231. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47–52
  232. Hustinx R, Smith RJ, Benard F, et al. Can the standardized uptake value characterize primary brain tumors on FDG-PET?. Eur J Nucl Med. 1999;26:1501–1509
  233. Katschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodexyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–785
  234. Fulham MJ, Melisi JW, Nishimiya J, et al. Neuroimaging of juvenile pilocytic astrocytomas: An enigma. Radiol. 1993;189:221–225
  235. DeLaPaz RL, Patronias NJ, Brooks RA, et al. Positron emission tomographic study of suppression of gray matter glucose utilization by brain tumors. AJNR Am J Neuroradiol. 1983;4:826–829
  236. Patronas NJ, DiChiro G, Smith BH, et al. Depressed cerebellar glucose metabolism in supratentorial tumors. Brain Res. 1984;291:93–101
  237. Otte A, Roelcke U, von Ammon K, et al. Crossed cerebellar diaschisis and brain tumor biochemistry studied with positron emission tomography, [18F]fluorodeoxyglucose and [11C]methionine. J Neurol Sci. 1998;156:73–77
  238. Newberg AB, Alavi A, Alavi J. Contralateral cortical diaschisis in a patient with cerebellar astrocytoma after radiation therapy. Clin Nucl Med. 2000;25:431–433
  239. Coleman RE, Hoffman JM, Hanson MW, et al. Clinical application of PET for the evaluation of brain tumors. J Nucl Med. 1991;32:616–622
  240. Barker FG, Chang SM, Valk PE, et al. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer. 1997;79:115–126
  241. (abstr) Patronas NJ, DiChiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Nucl Med. 1985;18:P64
  242. Herholz K, Ziffling P, Staffen W, et al. Uncoupling of hexose transport and phosphorylation in human gliomas demonstrated by PET. Eur J Cancer Clin Oncol. 1988;24:1139–1150
  243. DiChiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors. PET and neuropathologic studies. AJR Am J Roentgenol. 1988;150:189–198
  244. Doyle WK, Budinger TF, Valk PE, et al. Differentiation of cerebral radiation necrosis from tumor recurrence by (18F)FDG and 82Rb positron emission tomography. J Comput Axial Tomogr. 1987;11:563–570
  245. Rozental JM, Levine RL, Nickles RJ, et al. Changes in glucose uptake by malignant gliomas: preliminary study of prognostic significance. J Neurooncol. 1991;10:75–83
  246. Patronas NJ, DiChiro G, Brooks RA, et al. Work in progress: (18F) fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiol. 1982;144:885–889
  247. Valk PE, Budinger TF, Levin VA, et al. Positron emission tomography of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg. 1988;69:830–838
  248. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: Time for reevaluation of positron emission tomography?. AJNR Am J Neuroradiol. 1998;19:407–413
  249. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: Is it useful?. J Neurol Neurosurg Psychiatr. 1995;58:250–252
  250. Phillips PC, Dhawan V, Stother SC, et al. Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomography study. Ann Neurol. 1979;6:371–388
  251. Rozental JM, Robbins HI, Finlay J, et al. “Eight-Drugs-In-One-Day” chemotherapy administered before and after radiotherapy to adult patients with malignant glioma. Cancer. 1989;63:2475–2481
  252. Rozental JM, Robbins HI, Finlay J, et al. Eight-Drugs-In-One-Day chemotherapy in postirradiated adult patients with malignant gliomas. Med Pediatr Oncol. 1989;17:471–476
  253. Ogawa T, Uemura K, Shishido F, et al. Changes of cerebral blood flow and oxygen and glucose metabolism following radiochemotherapy of gliomas. A PET study. J Comput Assist Tomogr. 1988;12:290–297
  254. De Witte O, Hildebrand J, Luxen A, et al. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer. 1994;74:2836–2842
  255. Hinkin CH, van Gorp WG, Mandelkern MA, et al. Cerebral metabolic change in patients with AIDS: report of a six-month follow-up using positron-emission tomography. J of Neuropsychiatry Clin Neurosci. 1995;7:180–187
  256. van Gorp WG, Mandelkern MA, Gee M, et al. Cerebral metabolic dysfunction in AIDS: findings in a sample with and without dementia. J Neuropsychiatry Clin Neurosci. 1992;4:280–287
  257. Heald AE, Hoffman JM, Bartlett JA, et al. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS. 1996;7:337–346
  258. Kramer EL, Sanger JJ. Brain imaging in acquired immunodeficiency syndrome dementia complex. Semin Nucl Med. 1990;20:353–363
  259. Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med. 1993;34:567–575
  260. O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575–1583
  261. Villringer K, Jager H, Dichgans M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comp Assist Tomogr. 1995;19:532–536
  262. (suppl) Phelps ME, Mazziotta JC, Baxter L, et al. Positron emission tomographic study of affective disorders. Problems and strategies. Ann Neurol. 1984;15:S149–S156
  263. Kumar A, Newberg A, Alavi A, et al. Regional cerebral glucose metabolism in late life depression and Alzheimer's disease: A preliminary positron emission tomography study. Proc Natl Acad Sci U S A. 1993;90:7019–7023
  264. Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824–827
  265. Ho AP, Gillin JC, Buchsbaum MS, et al. Brain glucose metabolism during non-rapid eye movement sleep in major depression. A positron emission tomography study. Arch Gen Psychiatr. 1996;53:645–652
  266. Osuch EA, Ketter TA, Kimbrell TA, et al. Regional cerebral metabolism associated with anxiety symptoms in affective disorder patients. Biol Psychiatr. 2000;48:1020–1023
  267. Brody AL, Saxena S, Silverman DH, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatr Res. 1999;91:127–139
  268. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biol Psychiatr. 2000;48:830–843
  269. Wu J, Buchsbaum MS, Gillin JC, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulated and medial prefrontal cortex. Am J Psychiatr. 1999;156:1149–1158
  270. Smith GS, Reynolds CF, Pollock B, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatr. 1999;156:683–689
  271. Baxter LR, Phelps ME, Mazziotta JC, et al. Cerebral metabolic rates for glucose in mood disorders. Arch Gen Psychiatr. 1985;42:441–447
  272. Schwartz JM, Baxter LR, Mazziotta JC, et al. The differential diagnosis of depression. Relevance of positron emission tomography studies of cerebral glucose metabolism to the bipolar-unipolar dichotomy. JAMA. 1987;258:1368–1374
  273. Buchsbaum M, Wu J, Haier R, et al. Positron emission tomography assessment of effects of benzodiazepines on regional glucose metabolic rate in patients with anxiety disorder. Life Sci. 1986;40:2393–2400
  274. Morris P, Rapoport GI. Neuroimaging and affective disorder in late life: A review. Can J Psychiatr. 1990;35:347–354
  275. Liddle PF. PET scanning and schizophrenia—what progress?. Psychiatrological Med. 1992;22:557–560
  276. Sedvall G. The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacol. 1992;7:41–54
  277. Cleghorn JM, Zipursky RB, List SJ. Structural and functional brain imaging in schizophrenia. J Psychiatr Neurosci. 1991;16:53–74
  278. Kim JJ, Mohamed S, Andreasen NC, et al. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. Am J Psychiatr. 2000;157:542–548
  279. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand. 1974;50:425–462
  280. Andreasen NC, O'Leary DS, Flaum M, et al. Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 1997;349:1730–1734
  281. Gur RE, Resnick SM, Alavi A, et al. Regional brain function in schizophrenia I. A positron emission tomography study. Arch Gen Psychiatr. 1987;44:119–125
  282. Sheppard G, Gruzelier J, Manchanda R, et al. Positron emission tomographic scanning in predominantly never-treated acute schizophrenic patients. Lancet. 1983;2:1448–1452
  283. Wiesel F-A, Wik G, Sjogren I, et al. Altered relationships between metabolic rates of glucose in brain regions of schizophrenic patients. Acta Psychiatr Scand. 1987;76:642–647
  284. Wiesel FA, Wik G, Sjogren I, et al. Regional brain glucose metabolism in drug-free schizophrenic patients and clinical correlates. Acta Psychiatr Scand. 1987;76:628–641
  285. Volkow ND, Wolf AP, Van Gelder P, et al. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatr. 1987;144:151–158
  286. McGuire PK, Quested DJ, Spence SA, et al. Pathophysiology of ‘positive’ thought disorder in schizophrenia. Br J Psychiatr. 1998;173:231–235
  287. Buchanan RW, Breier A, Kirkpatrick B, et al. The deficit syndrome. Functional and structural characteristics. Schizoprenia Res. 1991;4:400–401
  288. Schroder J, Buchsbaum MS, Siegel BV, et al. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schiz Res. 1996;19:41–53
  289. Spence SA, Hirsch SR, Brooks DJ, et al. Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of ‘hypofrontality’ with recovery from acute schizophrenia. Br J Psychiatr. 1998;172:316–323
  290. Sabri O, Erkwoh R, Schreckenberger M, et al. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet. 1997;349:1735–1739
  291. Haznedar MM, Buchsbaum MS, Luu C, et al. Decreased anterior cingulate gyrus metabolic rate in schizophrenia. Am J Psychiatr. 1997;154:682–684
  292. Early TS, Reiman EM, Raichle ME, et al. Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proc Natl Acad Sci USA. 1987;84:561–563
  293. Hazlett EA, Buchsbaum MS, Byne W, et al. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am J Psychiatr. 1999;156:1190–1199
  294. Buchsbaum MS, Someya T, Teng CY, et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatr. 1996;153:191–199
  295. Liddle PF, Friston KJ, Frith CD, et al. Cerebral blood flow and mental processes in schizophrenia. J R Soc Med. 1992;85:224–227
  296. Liddle PF, Friston KJ, Frith CD, et al. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatr. 1992;160:179–186
  297. Katz M, Buchsbaum MS, Siegel BV, et al. Correlational patterns of cerebral glucose metabolism in never-medicated schizophrenics. Neuropsychobiology. 1996;33:1–11
  298. Siegel BV, Buchsbaum MS, Bunney WE, et al. Corticalstriatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatr. 1993;150:1325–1336
  299. Gur RE, Chin S. Laterality in functional brain imaging studies of schizophrenia. Schizophr Bull. 1999;25:141–156
  300. Gur RE, Resnick SM, Gur RC, et al. Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography. Arch Gen Psychiatr. 1987;44:126–129
  301. Gur RE, Resnick SM, Gur RC. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia. Relationship to symptom specificity. Psychiatr Res. 1989;27:325–334
  302. Cohen RM, Semple WE, Gross M, et al. From syndrome to illness. Delineating the pathophysiology of schizophrenia with PET. Schizophr Bull. 1988;14:169–176
  303. Cohen RM, Semple WE, Gross M, et al. Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 1987;43:2031–2039
  304. DeLisi LE, Buchsbaum MS, Holcomb HH, et al. Increased temporal lobe glucose use in chronic schizophrenic patients. Biol Psychiatr. 1989;25:835–851
  305. Gunther W. MRI-SPECT and PET-EEG findings on brain dysfunction in schizophrenia. Prog Neuropsychiatropharmacol Biol Psychiatr. 1992;16:445–462
  306. Siegel BV, Nuechterlein KH, Abel L, et al. Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenics, and controls. Schiz Res. 1995;17:85–94
  307. Carter CS, Mintum M, Nichols T, et al. Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: [15O]H2O PET study during single-trial Stroop task performance. Am J Psychiatr. 1997;154:1670–1675
  308. Artiges E, Martinot JL, Verdys M, et al. Altered hemispheric functional dominance during word generation in negative schizophrenia. Schizophr Bull. 2000;26:709–721
  309. Heckers S, Curran T, Goff D, et al. Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biol Psychiatr. 2000;48:651–657
  310. Crespo-Facorro B, Paradiso S, Andreasen NC, et al. Recalling word lists reveals “cognitive dysmetria” in schizophrenia: A positron emission tomography study. Am J Psychiatr. 1999;156:386–392
  311. Heckers S, Goff D, Schacter DL, et al. Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch Gen Psychiatr. 1999;56:1117–1123
  312. Carter CS, Perlstein W, Ganguli R, et al. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatr. 1998;155:1285–1287
  313. Volkow ND, Wolf AP, Brodie JD, et al. Brain interactions in chronic schizophrenics under resting and activation conditions. Schizophr Res. 1988;1:47–53
  314. Andreasen NC, O'Leary DS, Cizadlo T, et al. Schizophrenia and cognitive dysmetria: A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci USA. 1996;93:9985–9990
  315. Artiges E, Salame P, Recasens C, et al. Working memory control in patients with schizophrenia: a PET study during a random number generation task. Am J Psychiatr. 2000;157:1517–1519
  316. Heckers S, Rauch SL, Goff D, et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nature Neurosci. 1998;1:318–323
  317. Fletcher PC, McKenna PJ, Frith CD, et al. Brain activations in schizophrenia during a graded memory task studied with functional neuroimaging. Arch Gen Psychiatr. 1998;55:1001–1008
  318. Ragland JD, Gur RC, Glahn DC, et al. Frontotemporal cerebral blood flow change during executive and declarative memory tasks in schizophrenia: A positron emission tomography study. Neuropsychology. 1998;12:399–413
  319. Volkow ND, Brodie JD, Wolf AP, et al. Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. J Neurol Neurosurg Psychiatr. 1986;49:1199–1202
  320. Resnick SM, Gur RE, Alavi A, et al. Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatr Res. 1988;24:1–11
  321. Buchsbaum MS, Potkin SG, Siegel BV, et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatr. 1992;49:966–974
  322. Bartlett EJ, Brodie JD, Simkowitz P, et al. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiatr. 1998;155:337–343
  323. Baxter L, Schwartz J, Mazziotta J, et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry. 1988;145:1560–1563
  324. Nordahl TE, Benkelfat C, Semple W, et al. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology. 1989;2:23–28
  325. Swedo SE, Schapiro MB, Grady CL, et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psych. 1989;46:518–523
  326. Samson Y, Baron JC, Feline A, et al. Local cerebral glucose utilization in chronic alcoholics, a positron tomography study. J Neurol Neurosurg Psychiatry. 1986;49:1165–1170
  327. Sach H, Russel JAG, Christman DR, et al. Alterations in regional cerebral glucose metabolic rate in non-Korsakoff chronic alcoholism. Arch Neurol. 1987;44:1242–1251
  328. Wik G, Borg S, Sjogren I, et al. Positron emission tomography determination of regional cerebral glucose metabolism in alcohol-dependent men and healthy controls using 11C-glucose. Acta Psychiatr Scand. 1988;78:234–241
  329. Volkow ND, Fowler JS. Neuropsychiatric disorders. Investigation of schizophrenia and substance abuse. Semin Nucl Med. 1992;22:254–267
  330. Wang GJ, Volkow ND, Fowler JS, et al. Regional cerebral metabolism in female alcoholics of moderate severity does not differ from that of controls. Alcoholism Clin Exp Res. 1998;22:1850–1854
  331. Gilman S, Adams K, Koeppe RA, et al. Cerebellar hypometabolism in alcoholic cerebellar degeneration studied with FDG and PET. Neurology. 1988;38:365
  332. Volkow ND, Wang G-J, Hitzemann R, et al. Decreased cerebral response to inhibitory neurotransmission in alcoholics. Am J Psychiatry. 1993;150:417–422
  333. Johnson-Greene D, Adams KM, Gilman S, et al. Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism. J Clin Exp Neuropsychol. 1997;19:378–385
  334. Volkow ND, Wang GJ, Hitzemann R, et al. Recovery of brain glucose metabolism in detoxified alcoholics. Am J Psychiatry. 1994;151:178–183
  335. Volkow ND, Hitzemann R, Wolf AP, et al. Acute effects of ethanol on regional brain glucose metabolism and transport. Psychiatry Res. 1990;35:39–48
  336. Johanson CE, Fishman MW. The pharmacology of cocaine related to its abuse. Pharmacol Rev. 1989;41:3–52
  337. London ED, Bonson KR, Ernst M, et al. Brain imaging studies of cocaine abuse: Implications for medication development. Crit Rev Neurobiol. 1999;13:227–242
  338. London ED, Cascella NG, Wong DF, et al. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]-fluorodeoxyglucose. Arch Gen Psychiatry. 1990;47:567–574
  339. Volkow ND, Hitzemann R, Wang GJ, et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse. 1992;11:184–190
  340. Volkow ND, Fowler JS, Wolf AP, et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psych. 1991;148:621–626

PII: S0001-2998(02)80037-X

doi: 10.1053/snuc.2002.29276

Seminars in Nuclear Medicine
Volume 32, Issue 1 , Pages 13-34 , January 2002

Article Tools